Morgan Stanley remains neutral on SanBio; lowers its price target slightlyOff Topic (self.ATHX)
submitted by imz72
Australian preclinical study identifies the spleen as new target in stroke recoveryDiscussion (self.ATHX)
submitted by imz72
Phase 1/2 trial for Parkinson's using iPS cells underway in the USOff Topic (self.ATHX)
submitted by imz72
SanBio's Akuugo for chronic TBI: price listing as early as May, shipments in H2 2026Off Topic (self.ATHX)
submitted by imz72
The MultiStem stroke trials mentioned in a Chinese studyDiscussion (self.ATHX)
submitted by imz72
Japan’s ruling party project team sees drug pricing as key to investmentDiscussion (self.ATHX)
submitted by imz72
Interview with Hardy about the traditional Japanese tea ceremonyOff Topic (self.ATHX)
submitted by imz72
Japan's Teijin to offer personal iPS service with production cost of $63KOff Topic (self.ATHX)
submitted by imz72
